Eli Lilly and Co. CEO John Lechleiter said the company is "very much considering" developing follow-on biologics but clarified that the firm has yet to include such products in its pipeline. The drugmaker "could do particularly well" in such a venture because of its protein-engineering capabilities, said Steven Paul, president of Lilly Research Laboratories.

Related Summaries